These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 23638622)

  • 1. Raloxifene modifies the insulin sensitivity and lipid profile of postmenopausal insulin resistant women.
    Grover-Páez F; Zavalza-Gómez AB; Anaya-Prado R
    Gynecol Endocrinol; 2013 Jul; 29(7):674-7. PubMed ID: 23638622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial.
    Engin-Ustün Y; Ustün Y; Meydanli MM; Kafkasli A
    Gynecol Endocrinol; 2006 Dec; 22(12):676-9. PubMed ID: 17162709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
    Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
    O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
    Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia.
    Kulkarni J; Gurvich C; Lee SJ; Gilbert H; Gavrilidis E; de Castella A; Berk M; Dodd S; Fitzgerald PB; Davis SR
    Psychoneuroendocrinology; 2010 Sep; 35(8):1142-7. PubMed ID: 20171784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
    Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL
    Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
    Zheng S; Wu Y; Zhang Z; Yang X; Hui Y; Zhang Y; Chen S; Deng W; Liu H; Ekangaki A; Stocks J; Harper K; Liu J
    Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
    Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene.
    Tommaselli GA; Di Carlo C; Di Spiezio Sardo A; Bifulco G; Cirillo D; Guida M; Capasso R; Nappi C
    Menopause; 2006; 13(4):660-8. PubMed ID: 16837888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
    Usall J; Huerta-Ramos E; Iniesta R; Cobo J; Araya S; Roca M; Serrano-Blanco A; Teba F; Ochoa S
    J Clin Psychiatry; 2011 Nov; 72(11):1552-7. PubMed ID: 21903021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study.
    Duschek EJ; de Valk-de Roo GW; Gooren LJ; Netelenbos C
    Fertil Steril; 2004 Aug; 82(2):384-90. PubMed ID: 15302288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women.
    Lee CC; Kasa-Vubu JZ; Supiano MA
    J Am Geriatr Soc; 2003 May; 51(5):683-8. PubMed ID: 12752845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
    Verhoeven MO; Teerlink T; Kenemans P; Vogelvang TE; van der Mooren MJ;
    Menopause; 2007; 14(2):235-42. PubMed ID: 17146377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids.
    Oztas E; Kurtay G
    Arch Gynecol Obstet; 2011 Jan; 283(1):71-7. PubMed ID: 20012308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
    Draper MW; Flowers DE; Huster WJ; Neild JA; Harper KD; Arnaud C
    J Bone Miner Res; 1996 Jun; 11(6):835-42. PubMed ID: 8725181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of body fat distribution by waist circumference, dual-energy X-ray absorptiometry and ultrasonography to insulin resistance by homeostasis model assessment and lipid profile in obese and non-obese postmenopausal women.
    dos Santos RE; Aldrighi JM; Lanz JR; Ferezin PC; Marone MM
    Gynecol Endocrinol; 2005 Nov; 21(5):295-301. PubMed ID: 16373250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.